These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

458 related items for PubMed ID: 19540162

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.
    C Kitchener H, Canfell K, Gilham C, Sargent A, Roberts C, Desai M, Peto J.
    Health Technol Assess; 2014 Apr; 18(23):1-196. PubMed ID: 24762804
    [Abstract] [Full Text] [Related]

  • 3. ARTISTIC: a randomised trial of human papillomavirus (HPV) testing in primary cervical screening.
    Kitchener HC, Almonte M, Gilham C, Dowie R, Stoykova B, Sargent A, Roberts C, Desai M, Peto J, ARTISTIC Trial Study Group.
    Health Technol Assess; 2009 Nov; 13(51):1-150, iii-iv. PubMed ID: 19891902
    [Abstract] [Full Text] [Related]

  • 4. Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial.
    Ronco G, Giorgi-Rossi P, Carozzi F, Confortini M, Dalla Palma P, Del Mistro A, Ghiringhello B, Girlando S, Gillio-Tos A, De Marco L, Naldoni C, Pierotti P, Rizzolo R, Schincaglia P, Zorzi M, Zappa M, Segnan N, Cuzick J, New Technologies for Cervical Cancer screening (NTCC) Working Group.
    Lancet Oncol; 2010 Mar; 11(3):249-57. PubMed ID: 20089449
    [Abstract] [Full Text] [Related]

  • 5. HPV testing compared with routine cytology in cervical screening: long-term follow-up of ARTISTIC RCT.
    Gilham C, Sargent A, Kitchener HC, Peto J.
    Health Technol Assess; 2019 Jun; 23(28):1-44. PubMed ID: 31219027
    [Abstract] [Full Text] [Related]

  • 6. Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomised controlled trial.
    Rijkaart DC, Berkhof J, Rozendaal L, van Kemenade FJ, Bulkmans NW, Heideman DA, Kenter GG, Cuzick J, Snijders PJ, Meijer CJ.
    Lancet Oncol; 2012 Jan; 13(1):78-88. PubMed ID: 22177579
    [Abstract] [Full Text] [Related]

  • 7. Effect of Screening With Primary Cervical HPV Testing vs Cytology Testing on High-grade Cervical Intraepithelial Neoplasia at 48 Months: The HPV FOCAL Randomized Clinical Trial.
    Ogilvie GS, van Niekerk D, Krajden M, Smith LW, Cook D, Gondara L, Ceballos K, Quinlan D, Lee M, Martin RE, Gentile L, Peacock S, Stuart GCE, Franco EL, Coldman AJ.
    JAMA; 2018 Jul 03; 320(1):43-52. PubMed ID: 29971397
    [Abstract] [Full Text] [Related]

  • 8. Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study.
    Castle PE, Stoler MH, Wright TC, Sharma A, Wright TL, Behrens CM.
    Lancet Oncol; 2011 Sep 03; 12(9):880-90. PubMed ID: 21865084
    [Abstract] [Full Text] [Related]

  • 9. [Health technology assessment report. Use of liquid-based cytology for cervical cancer precursors screening].
    Ronco G, Confortini M, Maccallini V, Naldoni C, Segnan N, Sideri M, Zappa M, Zorzi M, Calvia M, Giorgi Rossi P.
    Epidemiol Prev; 2012 Sep 03; 36(5 Suppl 2):e1-e33. PubMed ID: 23139163
    [Abstract] [Full Text] [Related]

  • 10. Extension of cervical screening intervals with primary human papillomavirus testing: observational study of English screening pilot data.
    Rebolj M, Cuschieri K, Mathews CS, Pesola F, Denton K, Kitchener H, HPV pilot steering group.
    BMJ; 2022 May 31; 377():e068776. PubMed ID: 35640960
    [Abstract] [Full Text] [Related]

  • 11. Liquid-based cytology and human papillomavirus testing: a pooled analysis using the data from 13 population-based cervical cancer screening studies from China.
    Pan QJ, Hu SY, Guo HQ, Zhang WH, Zhang X, Chen W, Cao J, Jiang Y, Zhao FH, Qiao YL.
    Gynecol Oncol; 2014 May 31; 133(2):172-9. PubMed ID: 24631450
    [Abstract] [Full Text] [Related]

  • 12. Cervical screening with primary HPV testing or cytology in a population of women in which those aged 33 years or younger had previously been offered HPV vaccination: Results of the Compass pilot randomised trial.
    Canfell K, Caruana M, Gebski V, Darlington-Brown J, Heley S, Brotherton J, Gertig D, Jennett CJ, Farnsworth A, Tan J, Wrede CD, Castle PE, Saville M.
    PLoS Med; 2017 Sep 31; 14(9):e1002388. PubMed ID: 28926579
    [Abstract] [Full Text] [Related]

  • 13. Safety of extending screening intervals beyond five years in cervical screening programmes with testing for high risk human papillomavirus: 14 year follow-up of population based randomised cohort in the Netherlands.
    Dijkstra MG, van Zummeren M, Rozendaal L, van Kemenade FJ, Helmerhorst TJ, Snijders PJ, Meijer CJ, Berkhof J.
    BMJ; 2016 Oct 04; 355():i4924. PubMed ID: 27702796
    [Abstract] [Full Text] [Related]

  • 14. Primary cervical cancer screening with HPV testing compared with liquid-based cytology: results of round 1 of a randomised controlled trial -- the HPV FOCAL Study.
    Ogilvie GS, Krajden M, van Niekerk DJ, Martin RE, Ehlen TG, Ceballos K, Smith LW, Kan L, Cook DA, Peacock S, Stuart GC, Franco EL, Coldman AJ.
    Br J Cancer; 2012 Dec 04; 107(12):1917-24. PubMed ID: 23169286
    [Abstract] [Full Text] [Related]

  • 15. Protocol for Compass: a randomised controlled trial of primary HPV testing versus cytology screening for cervical cancer in HPV-unvaccinated and vaccinated women aged 25-69 years living in Australia.
    Canfell K, Saville M, Caruana M, Gebski V, Darlington-Brown J, Brotherton J, Heley S, Castle PE.
    BMJ Open; 2018 Jan 26; 8(1):e016700. PubMed ID: 29374658
    [Abstract] [Full Text] [Related]

  • 16. Detection rates of precancerous and cancerous cervical lesions within one screening round of primary human papillomavirus DNA testing: prospective randomised trial in Finland.
    Leinonen MK, Nieminen P, Lönnberg S, Malila N, Hakama M, Pokhrel A, Laurila P, Tarkkanen J, Anttila A.
    BMJ; 2012 Nov 29; 345():e7789. PubMed ID: 23197596
    [Abstract] [Full Text] [Related]

  • 17. Efficacy of HPV DNA testing with cytology triage and/or repeat HPV DNA testing in primary cervical cancer screening.
    Naucler P, Ryd W, Törnberg S, Strand A, Wadell G, Elfgren K, Rådberg T, Strander B, Forslund O, Hansson BG, Hagmar B, Johansson B, Rylander E, Dillner J.
    J Natl Cancer Inst; 2009 Jan 21; 101(2):88-99. PubMed ID: 19141778
    [Abstract] [Full Text] [Related]

  • 18. A comparison of HPV DNA testing and liquid based cytology over three rounds of primary cervical screening: extended follow up in the ARTISTIC trial.
    Kitchener HC, Gilham C, Sargent A, Bailey A, Albrow R, Roberts C, Desai M, Mather J, Turner A, Moss S, Peto J.
    Eur J Cancer; 2011 Apr 21; 47(6):864-71. PubMed ID: 21334200
    [Abstract] [Full Text] [Related]

  • 19. Long term duration of protective effect for HPV negative women: follow-up of primary HPV screening randomised controlled trial.
    Elfström KM, Smelov V, Johansson AL, Eklund C, Nauclér P, Arnheim-Dahlström L, Dillner J.
    BMJ; 2014 Jan 16; 348():g130. PubMed ID: 24435414
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.